Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A dual-labeling technique combining two fluorophores used primarily in neurosurgery for tumor visualization. 5-aminolevulinic acid (5-ALA) is metabolized within tumor cells to protoporphyrin IX (PPIX), which fluoresces red under blue light (400nm), while sodium fluorescein extravasates in areas of blood-brain barrier disruption, emitting yellow-green fluorescence under 560nm light. This combination provides complementary information on tumor cells and blood-brain barrier integrity, allowing better discrimination between necrosis, proliferating tumor, infiltrating tumor, and peritumoral edema during surgical procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-aminolevulinic acid + sodium fluorescein.